Literature DB >> 19854165

Glanzmann thrombasthenia: an update.

Massimo Franchini1, Emmanuel J Favaloro, Giuseppe Lippi.   

Abstract

Glanzmann thrombasthenia (GT) is a rare autosomal recessive disorder characterized by qualitative or quantitative abnormalities of the platelet membrane glycoprotein (GP) IIb/IIIa. Physiologically, this platelet receptor normally binds several adhesive plasma proteins, and this facilitates attachment and aggregation of platelets to ensure thrombus formation at sites of vascular injury. The lack of resultant platelet aggregation in GT leads to mucocutaneous bleeding whose manifestation may be clinically variable, ranging from easy bruising to severe and potentially life-threatening hemorrhages. In this review we discuss the main characteristics of GT, focusing on molecular defects, diagnostic evaluation and treatment strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19854165     DOI: 10.1016/j.cca.2009.10.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.

Authors:  Giovanni Di Minno; Rainer B Zotz; Roseline d'Oiron; Niels Bindslev; Matteo Nicola Dario Di Minno; Man-Chiu Poon
Journal:  Haematologica       Date:  2015-05-22       Impact factor: 9.941

2.  Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia.

Authors:  Sibel Kabukçu Hacıoğlu; Mehmet Hilmi Doğu; İsmail Sarı; Ali Keskin
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

Review 3.  Recombinant activated factor VII in clinical practice: a 2014 update.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

Review 4.  Platelets: still a therapeutical target for haemostatic disorders.

Authors:  Reinaldo Barros Geraldo; Plínio Cunha Sathler; André Luiz Lourenço; Max Seidy Saito; Lucio M Cabral; Pabulo Henrique Rampelotto; Helena Carla Castro
Journal:  Int J Mol Sci       Date:  2014-10-07       Impact factor: 5.923

5.  In silico analysis of Glanzmann variants of Calf-1 domain of αIIbβ3 integrin revealed dynamic allosteric effect.

Authors:  Matthieu Goguet; Tarun Jairaj Narwani; Rachel Petermann; Vincent Jallu; Alexandre G de Brevern
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

6.  Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: Association with bleeding symptoms.

Authors:  Deepti Mutreja; Rahul Kumar Sharma; Abhishek Purohit; Mukul Aggarwal; Renu Saxena
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

7.  Study of the Relationship between HPA-1 and HPA-5 Gene Polymorphisms and Refractory to Platelet Therapy and Recombinant Factor VII in Glanzmann Thrombasthenia Patients in Southeast of Iran.

Authors:  Majid Naderi; Manizheh Habibpour; Shaban Alizadeh; Zahra Kashani Khatib; Akbar Dorgalaleh; Mohammed Awal Issah; Fatemeh Naadali
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

Review 8.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

9.  [Glanzmann thrombasthenia: about 11 cases].

Authors:  Jean-Louis Ntumba Mukendi; Souad Benkirane; Azlarab Masrar
Journal:  Pan Afr Med J       Date:  2015-08-11

10.  Glanzmann thrombasthenia associated with human immunodeficiency virus-positive patient.

Authors:  Rakesh Kumar Manne; Kannan Natarajan; Rajendra Patil; Venkata Sarath Prathi; Swapna Sridevi Beeraka; Venkata Suneel Kumar Kolaparthi
Journal:  Int J Prev Med       Date:  2014-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.